The digene HC2 CT-GC Dual ID DNA Test provides high clinical sensitivity and specificity, comparable to more complex target-amplification methods (see tables).
The digene HC2 CT-GC Dual ID DNA Test is recognized by the American Medical Association (AMA) and reimbursed using "amplified probe technique" CPT codes (when appropriate).
The digene HC2 CT-GC Dual ID DNA Test kit contains the necessary probes and reagents to screen for Chlamydia trachomatis (CT) or Neisseria gonorrhoeae (GC), with an in vitro nucleic acid hybridization assay with signal amplification using chemiluminescence. The CT and GC probe cocktails contain probe mixtures specifically chosen to eliminate or minimize cross-reactivity with DNA sequences from human cells, other bacterial species, Chlamydia species other than Chlamydia trachomatis, or Neisseria species other than Neisseria gonorrhoeae.
Cervical specimens for use with the digene HC2 CT-GC Dual ID DNA Test are collected and transported using the digene HC2 DNA Collection Device or digene Female Swab Specimen Collection Kit.
The digene HC2 CT-GC Dual ID DNA Test process is simple, from denaturation to hybridization and hybrid capture. After the final denaturation, the procedure can be fully automated on the Rapid Capture System through to sample detection. Detection is then carried out manually on a luminometer.
The digene HC2 CT-GC Dual ID DNA Test is for separate qualitative detection of Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (GC) DNA in the same cervical specimen. The kit contains separate tests for CT and GC, which can be used as stand-alone tests. The tests may also be used as follow-up for differentiation of CT and GC in specimens that initially tested positive using the digene HC2 CT/GC DNA Test.
The digene HC2 CT-GC Dual ID DNA Test is indicated for use in identifying symptomatic or asymptomatic women with Chlamydia trachomatis (CT) and/or Neisseria gonorrhoeae (GC) infection.